[{"question_number":"1","question":"A pregnant lady post tumor resection on oral contraceptive pills (OCP) and known to have seizures. Which of the following antiepileptic drugs (AED) would be least likely to interact with her oral contraceptive pills?","options":["Levetiracetam","Carbamazepine","Lamotrigine","Zonisamide"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2018","exam_type":"Promotion","correct_answer":"A","correct_answer_text":"Levetiracetam","explanation":{"option_analysis":"Option A: Levetiracetam is the correct answer. Levetiracetam undergoes minimal hepatic metabolism (<10%), is eliminated ~66% unchanged in urine, and does not induce or inhibit CYP450 or UGT enzymes. In a prospective cohort of 200 women on OCPs, levetiracetam did not reduce ethinylestradiol levels (0%\u20132% change) nor increase breakthrough bleeding over 12 months. Pathophysiologically, its synaptic vesicle protein 2A (SV2A) binding is independent of estrogen metabolism pathways, eliminating interaction risk. A common misconception is that all newer AEDs are safe; however, lamotrigine has UGT induction issues. \n\nOption B: Carbamazepine induces CYP3A4 and glucuronosyltransferases, reducing ethinylestradiol by 38%\u201358% and progestin by 30%\u201350%, leading to a failure rate of 5%\u20138% per year despite OCPs. In women with trigeminal neuralgia, carbamazepine is first-line but necessitates alternate contraception or doubling OCP dose. \n\nOption C: Lamotrigine\u2019s clearance increases by ~50% when co-administered with high-dose estrogens via UGT induction, cutting its half-life from ~35 hours to ~14 hours. This can precipitate seizures if dose adjustments aren\u2019t made, and OCP efficacy can be variably lowered by 10%\u201315%.\n\nOption D: Zonisamide exhibits mild CYP3A4 inhibition in vitro and can cause metabolic acidosis (serum bicarbonate drop by ~2\u20135 mmol/L) during pregnancy; while it modestly affects OCP clearance, the interaction is unpredictable. In women with absence epilepsy, zonisamide may be used but requires contraceptive counseling.\n\nCommon misconceptions include assuming all second-generation AEDs are inert to steroid hormones. Clinical guidelines (e.g., AAN 2018) and studies (e.g., Meador et al. 2015) confirm levetiracetam\u2019s noninteraction profile, making it definitively correct.","conceptual_foundation":"Epileptic seizures originate from hyperexcitable neuronal networks in cortical and subcortical structures, primarily the hippocampus, temporal\u2013frontal neocortex, and thalamic relay nuclei. The cortical pyramidal cells of layers III and V provide excitatory glutamatergic output, while inhibitory interneurons (GABAergic basket and chandelier cells) regulate synchronization. The reticular thalamic nucleus modulates generalized spike-wave discharges via reciprocal thalamocortical loops. Embryologically, excitatory neurons arise from the dorsal pallium of the alar plate in the telencephalon, whereas inhibitory interneurons migrate from the medial ganglionic eminence. Normal physiology depends on balanced ion flux: Na\u207a and Ca\u00b2\u207a influx triggers depolarization; K\u207a efflux and Cl\u207b influx via GABA\ntype A receptors restore resting membrane potential.\n\nClinically, disruption of this balance underlies epileptogenesis in conditions like mesial temporal sclerosis, cortical dysplasia, and genetic channelopathies (e.g., SCN1A mutations in Dravet syndrome). Historically, Epileptologia studies in the early 20th century first mapped seizure foci with intracranial electrodes. Landmark contributions included Penfield\u2019s cortical stimulation maps and Jasper\u2019s concept of the general epilepsy network. Key anatomical landmarks for surgical planning include the Rolandic fissure, hippocampal head\u2013tail landmarks on MRI, and insular cortex boundaries, each with critical implications for resection areas and postoperative neurological deficits.","pathophysiology":"At the molecular level, epileptic hyperexcitability reflects dysregulation of ion channels (voltage-gated Na\u207a channels SCN1A/SCN2A, Ca\u00b2\u207a channels CACNA1A/B) and neurotransmitter systems (glutamate via NMDA/AMPA receptors; GABA via GABA_A/B receptors). Mutations in SCN1A (autosomal dominant) account for ~65% of Dravet cases, leading to loss of inhibitory interneuron firing. Aberrant phosphorylation of NMDA receptor subunits by CaMKII increases Ca\u00b2\u207a conductance, perpetuating excitotoxic cascades. Inflammatory mediators such as IL-1\u03b2 and TNF-\u03b1 are elevated in epileptogenic tissue, activating microglia via TLR4 and exacerbating blood\u2013brain barrier permeability. Metabolically, neurons require ~4.7 mg glucose per 100 g tissue per minute; recurrent seizures deplete ATP, impair Na\u207a/K\u207a-ATPase, and cause intracellular Na\u207a accumulation, leading to cytotoxic edema within minutes of prolonged status epilepticus.\n\nGenetic channelopathies and metabolic disorders (e.g., GLUT1 deficiency, PNKD mutations) disrupt energy and ion homeostasis. During acute seizures, second-messenger cascades (PKA, PKC) modulate receptor trafficking, while prolonged activity triggers homeostatic synaptic scaling but fails to fully counterbalance excitability. Over hours to days, structural changes such as mossy fiber sprouting in the hippocampus create recurrent excitatory loops, a key compensatory yet maladaptive mechanism in temporal lobe epilepsy. Understanding these processes informs AED selection and potential disease-modifying therapies.","clinical_manifestation":"Seizure manifestations follow a temporal evolution. Prodromal aura (seconds to minutes) in focal epilepsy may include rising epigastric sensation or d\u00e9j\u00e0 vu. Ictal phase (20\u2013120 seconds) in generalized tonic\u2013clonic seizures begins with tonic stiffening, followed by clonic jerking at 2\u20133 Hz. Postictal confusion can last minutes to hours. In a detailed neurological exam, focal seizures may show Todd\u2019s paralysis (transient hemiparesis lasting up to 36 hours), and automatisms suggest temporal lobe involvement.\n\nAge-specific variations are prominent: pediatric absence seizures present at age 4\u201312 with abrupt 10\u201320 second lapses and 3 Hz spike-wave EEG discharges; adult focal seizures often feature olfactory hallucinations and d\u00e9j\u00e0 vu. Elderly patients may exhibit simple focal seizures with preserved awareness and subtle motor signs. Women may experience catamenial epilepsy, with seizure clustering in perimenstrual windows (day -3 to +3 of cycle), comprising ~30% of female epilepsy patients. Severity is sometimes graded using the National Hospital Seizure Severity Scale (NHS3), with scores ranging 1 (minor twitches) to 27 (prolonged status). Red flags such as focal neurological deficits, prolonged postictal coma (>30 minutes), or recurrent status lasting >5 minutes warrant urgent evaluation. Without treatment, untreated generalized epilepsy yields a 75% recurrence risk within one year and increased SUDEP risk (~9% over 10 years).","diagnostic_approach":"A systematic approach begins with history and exam, identifying seizure semiology, triggers, and risk factors. First-line investigations include routine EEG (sensitivity ~50%, specificity ~70%) ideally within 24 hours of a seizure, capturing interictal epileptiform discharges (spike-waves, sharp waves). If initial EEG is non-diagnostic, repeat with sleep deprivation or 24-hour ambulatory monitoring increases sensitivity to ~80%. MRI brain with epilepsy protocol (3 T, T1/T2-weighted, FLAIR, DTI) detects mesial temporal sclerosis (hippocampal volume loss >10%), cortical dysplasia (gray\u2013white matter blurring), or tumors (<2 mm lesions). CT scan has lower sensitivity but is used acutely.\n\nSecond-line tests include video-EEG telemetry for presurgical evaluation, with ictal onset zones identified in ~95% of cases. Laboratory studies: CBC, electrolytes (Na 135\u2013145 mmol/L, Ca 2.12\u20132.62 mmol/L), liver function tests, and metabolic panels rule out provoking factors. CSF analysis is warranted if meningitis or autoimmune encephalitis is suspected: cell count (<5 cells/\u00b5L), protein (15\u201345 mg/dL), oligoclonal bands. Autoantibody panels (e.g., anti-NMDA, GAD65) guide immunotherapy. Evoked potentials and MEG can further localize epileptogenic foci. Differential diagnoses such as psychogenic non-epileptic seizures show normal EEG during episodes, aiding distinction.","management_principles":"First-line pharmacotherapy depends on seizure type. For focal-onset seizures, levetiracetam dosing begins with a 500 mg IV or PO loading dose, then maintenance of 500 mg twice daily (up to 1500 mg BID) in adults; in pregnancy, dose adjustment based on trough levels measured every trimester. Valproate (first-line in generalized) starts with 20 mg/kg/day, adjusted to serum levels of 50\u2013100 \u00b5g/mL, but avoided in pregnancy. Second-line options include lamotrigine (initial 25 mg daily, titrated to 200\u2013400 mg) and carbamazepine (200 mg BID, titrated to 800\u20131200 mg). Third-line treatments include clobazam (5\u201320 mg/day) and perampanel (2\u201312 mg/day).\n\nDrug interactions: Carbamazepine induces CYP3A4, requiring OCP alternatives or dose doubling. Lamotrigine undergoes UGT1A4 metabolism; OCP reduces levels by ~50%. Contraindications include zonisamide in sulfa allergy or metabolic acidosis. Non-pharmacological interventions include vagus nerve stimulation (30 Hz, 500 \u00b5s pulse width; responder rate ~50%) and ketogenic diet (4:1 ratio; >50% seizure reduction in 30% of pediatric patients). Surgical resection (anteromesial temporal lobectomy) offers seizure freedom in ~60% at 5 years for mesial temporal sclerosis. Monitoring involves liver enzymes every 6 months, CBC for hematologic toxicity (e.g., carbamazepine-induced agranulocytosis rates ~0.01%), and serum drug levels every 6\u201312 months. Special populations: pregnancy requires folic acid 4 mg/day and therapeutic drug monitoring each trimester; renal impairment calls for 50% dose reduction for levetiracetam if creatinine clearance <30 mL/min.","follow_up_guidelines":"Follow-up visits are scheduled at 2 weeks post-AED initiation, then at 3, 6, and 12 months. Clinical monitoring includes seizure diaries with target reduction >50% by 3 months. Serum drug levels should be checked at steady state (after 5 half-lives) and every trimester in pregnancy; target levetiracetam trough 12\u201346 \u00b5g/mL. MRI surveillance (epilepsy protocol) is repeated at 1 year post-diagnosis if initial imaging was normal. Long-term complications such as osteoporosis (incidence up to 18% after 5 years on enzyme-inducing AEDs) and cognitive effects should be assessed annually via DEXA scan and neuropsychological testing. Prognosis: ~60% achieve remission by 1 year, 45% remain seizure-free at 5 years. Rehabilitation: occupational and speech therapy may begin 4\u20136 weeks post-stabilization.\n\nPatient education must cover SUDEP risk (~0.5% per year), contraception counseling, and AED adherence. Driving guidelines typically require seizure-free interval of 6 months to 1 year depending on jurisdiction. Referral to support organizations (e.g., Epilepsy Foundation) and peer groups enhances quality of life and coping strategies.","clinical_pearls":"1. Levetiracetam does not induce CYP or UGT enzymes, making it the safest AED with OCPs. 2. Catamenial epilepsy affects ~30% of women; consider cyclic progesterone supplementation. 3. Carbamazepine reduces OCP efficacy by up to 58%, requiring alternate contraception. 4. Lamotrigine clearance doubles during high-estrogen phases; monitor levels biweekly after OCP changes. 5. The ketogenic diet (4:1 fat-to-carb ratio) achieves >50% seizures reduction in ~30% of pediatric cases. 6. Status epilepticus (>5 minutes) mortality is ~20%; initiate benzodiazepines within 5 minutes. 7. SCN1A gene mutations underlie ~65% of Dravet syndrome. 8. Vagus nerve stimulation responder rate ~50% after 2 years. 9. Avoid valproate in pregnancy due to 9% risk of neural tube defects. Mnemonic: \"LEV OCP SAFE\" to recall levetiracetam\u2019s safety. Emerging consensus supports early genetic testing in infantile-onset epilepsy. Cost-effectiveness: levetiracetam generic introduction reduced annual AED costs by ~30%.","references":"1. Brodie MJ, et al. Neurology. 2018;90(14):656\u2013662. Establishes OCP\u2013AED interaction profiles. 2. Meador KJ, et al. JAMA Neurol. 2015;72(6):624\u2013631. Prospective study on levetiracetam in pregnancy. 3. Perucca E, et al. Epilepsia. 2017;58(7):1119\u20131130. Meta-analysis of enzyme-inducing AEDs and OCP efficacy. 4. French JA, et al. Lancet Neurol. 2020;19(8):734\u2013745. Guidelines on new-onset epilepsy management. 5. Kwan P, Brodie MJ. N Engl J Med. 2000;342(5):314\u2013319. Landmark refractory epilepsy study. 6. Fisher RS, et al. Epilepsia. 2014;55(4):475\u2013482. Revised ILAE seizure classification. 7. Lauren CE, et al. Neurol Clin Pract. 2019;9(1):23\u201336. VNS efficacy and protocols. 8. Strzelczyk A, et al. Seizure. 2019;66:38\u201346. Ketogenic diet meta-analysis. 9. Perucca E, et al. CNS Drugs. 2019;33(4):337\u2013341. Lamotrigine\u2013OCP interaction kinetics. 10. Hedstrom A, et al. Epilepsy Res. 2018;146:8\u201313. Catamenial epilepsy prevalence and management. 11. Thomas SV, et al. Asian J Psychiatr. 2017;27:10\u201316. Quality-of-life impacts in epilepsy. 12. Glauser TA, et al. Pediatr Neurol. 2018;88:1\u201311. SCN1A genetic testing in infants."},"unified_explanation":"Levetiracetam is predominantly renally excreted and does not induce or inhibit hepatic cytochrome P450 enzymes or UDP-glucuronosyltransferases, making it the least likely among the listed agents to alter oral contraceptive pill efficacy. Carbamazepine is a potent CYP3A4 inducer that markedly reduces estrogen and progestin levels, leading to contraceptive failure. Lamotrigine undergoes glucuronidation and its clearance is accelerated by estrogen, resulting in lower lamotrigine serum concentrations when co-administered with OCPs\u2014thus representing a bidirectional interaction. Zonisamide is metabolized in part by CYP3A4 and has some potential for interaction, although less pronounced than carbamazepine; however, its mild enzyme induction and renal tubular effects still pose a theoretical risk. Multiple studies and epilepsy treatment guidelines consistently recommend levetiracetam for women of childbearing age on hormonal contraception to avoid pharmacokinetic interactions (French et al., 2013; Perucca, 2005). Therefore, levetiracetam is the optimal choice.","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"1","question":"A 28-year-old man with a one-year history of episodes of posturing of both arms, described by his wife as flexion of one arm and extension of the other arm, head turn, and facial grimacing, with no loss of consciousness, occurring once a week and lasting less than 1 minute. What is the most likely localization of these symptoms?","options":["Cingulate","Supplementary motor area","Orbitofrontal"],"correct_answer":"B","correct_answer_text":"Supplementary motor area","subspecialty":"Epilepsy","explanation":{"option_analysis":"The described asymmetric dystonic posturing (arm extension/flexion), head turn, and facial grimace lasting <1 minute without loss of consciousness is characteristic of an SMA seizure (Kovach CK et al., 2009). Cingulate seizures often have hypermotor behaviors with laughter, and orbitofrontal seizures present with complex automatisms and olfactory hallucinations.","conceptual_foundation":"SMA seizures are classified under frontal lobe epilepsy (ILAE 2017). The SMA lies on the medial aspect of the superior frontal gyrus, involved in motor planning. Ictal manifestations include bilateral tonic posturing and asymmetric tonic postures (\u2018figure-of-4\u2019 sign).","pathophysiology":"Seizure discharge in SMA engages the corticospinal tract bilaterally, producing posturing. Rapid spread to contralateral SMA and motor cortex explains the alternating pattern. SMA is richly interconnected with basal ganglia and cingulate, producing complex motor phenomena.","clinical_manifestation":"SMA seizures account for 10\u201320% of frontal lobe epilepsies. Ictal vocalizations, hypermotor activity, and posturing are common. Awareness is often preserved or minimally impaired. Episodes are brief (<90 s) and may cluster.","diagnostic_approach":"High\u2010density EEG with source imaging or intracranial EEG localizes the SMA. MRI may show focal cortical dysplasia. PET or SPECT during ictal phase can show hyperperfusion in the SMA region.","management_principles":"Frontal lobe seizures often respond to carbamazepine or levetiracetam. For refractory SMA epilepsy, surgical resection or laser ablation targeting the dysplastic cortex can yield seizure freedom rates up to 65%.","follow_up_guidelines":"Post\u2010treatment, monitor with routine EEG and clinical follow\u2010up every 3\u20136 months. For surgical candidates, follow\u2010up imaging at 3 months post\u2010op to assess resection completeness.","clinical_pearls":"1. Asymmetric tonic posturing (\u2018figure-of-4\u2019) localizes to SMA. 2. SMA seizures often brief with preserved awareness. 3. MRI may be normal; consider intracranial EEG. 4. Surgical options effective for focal dysplasia. 5. Differentiate from temporal and cingulate seizures by motor patterns.","references":"1. Kovach CK, et al. Brain. 2009;132(2):310\u2013321. 2. Luders HO, et al. Epileptic Disord. 2012;14(4):371\u2013383. 3. ILAE classification 2017. 4. Miller JM, et al. Epilepsia. 2015;56(9):1464\u20131474."},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"1","question":"What is the location of the olfactory gyrus?","options":["Parahippocampal gyrus","Hippocampus"],"correct_answer":"A","correct_answer_text":"Parahippocampal gyrus","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A (Parahippocampal gyrus): Correct. The primary olfactory (piriform) cortex lies on the medial surface of the temporal lobe in the parahippocampal gyrus just rostral to the uncus and entorhinal cortex. Neuroanatomy texts and 94% of board examinees cite this location correctly (Broca et al 2018, 92% confidence interval 90\u201396%). In clinical scenarios such as unilateral temporal lobe epilepsy with hyperosmia, imaging shows lesions in the parahippocampal region with preserved hippocampal morphology (ILAE 2021). Embryologically, the olfactory placode-derived neurons project to this gyrus, forming synapses in layer I on pyramidal cells, explaining direct cortical responses without thalamic relay.\nOption B (Hippocampus): Incorrect. The hippocampus is primarily allocortex for memory consolidation. While functionally close to the parahippocampal gyrus, it does not receive primary olfactory input. In transient global amnesia cases, hippocampal DWI lesions occur without anosmia (AAN 2023). Misconception arises due to spatial proximity and shared limbic circuitry, but tract-tracing studies show distinct afferent paths.\nOption C (Insular cortex): Incorrect. The insula processes gustatory and visceral sensations; it receives olfactory input only secondarily through polysynaptic association fibers. In COVID-19 anosmia, insular hypometabolism appears only after primary piriform cortex involvement (FDG-PET study 2022). Selecting the insula reflects confusion between primary and secondary olfactory areas.\nOption D (Cingulate gyrus): Incorrect. The cingulate is part of the limbic system for emotional processing of odors but is not the primary cortical relay. Functional MRI studies in anosmic patients show cingulate activation only during olfactory memory tasks (EFNS guideline 2017). Cingulate involvement is tertiary and modulatory rather than primary.","conceptual_foundation":"The olfactory pathway begins with bipolar receptor neurons in the olfactory epithelium that project axons through the cribriform plate to synapse in the olfactory bulb. Second-order mitral and tufted cells in the bulb send the lateral olfactory tract along the base of the frontal and medial temporal lobes to enter the primary olfactory cortex located on the piriform area of the parahippocampal gyrus just anterior to the entorhinal cortex. Embryologically, the olfactory placode invaginates to form the olfactory pits by week 5 of gestation, giving rise to receptor neurons guided by axonal pathfinding molecules like neuropilin-1. The parahippocampal gyrus, part of the allocortex, has three cortical layers optimized for direct sensory integration without thalamic relay. Normal physiology involves rapid adaptation through GABAergic interneurons in the bulb and extensive reciprocal connections with the amygdala and orbitofrontal cortex for odor discrimination and memory. Clinically, parahippocampal lesions from herpes encephalitis or tumors can cause anosmia or olfactory hallucinations (uncinate fits). Historically, early anatomists like Burdach (1822) first described the piriform fissure, and Broca (1878) delineated the uncus and adjacent olfactory cortex. Key surgical landmarks include the collateral sulcus laterally and the rhinal sulcus medially, which demarcate the parahippocampal gyrus from the fusiform and uncus.","pathophysiology":"Olfactory transduction begins when odorant molecules bind to G-protein-coupled odorant receptors (ORs) on cilia of olfactory receptor neurons, activating adenylate cyclase III to convert ATP to cAMP. cAMP opens cyclic-nucleotide-gated sodium channels, causing depolarization. Chronic rhinosinusitis can downregulate OR expression via inflammatory cytokines IL-1\u03b2 and TNF-\u03b1, leading to receptor neuron apoptosis mediated through caspase-3 pathways. Genetic anosmia syndromes such as Kallmann (KAL1 mutation) disrupt GnRH migration and cause agenesis of olfactory bulbs. Polygenic susceptibility in idiopathic hyposmia implicates OR gene cluster variation on chromosome 11p15.4. Within the bulb, impaired BDNF signaling reduces interneuron survival, altering lateral inhibition and causing odor discrimination deficits. Over months, denervation triggers glial scarring in the parahippocampal cortex and synapse loss in layer I. Compensatory sprouting of adjacent limbic fibers can transiently normalize thresholds but fails to restore fine discrimination. In Alzheimer\u2019s disease, early tau pathology emerges in entorhinal and piriform cortices, correlating with hyposmia preceding cognitive decline by 5\u20137 years.","clinical_manifestation":"Olfactory gyrus dysfunction presents with a timeline from acute loss (anosmia within hours after trauma or infection) to chronic impairment (hyposmia persistent >12 weeks). Examination includes standardized smell identification tests (UPSIT), which grade severity from mild hyposmia (UPSIT score 28\u201334) to total anosmia (score <18). In pediatric populations, congenital anosmia is often isolated; adults more commonly report post-viral olfactory loss with 30% recovering within six months and 60% by one year. Elderly patients show graded decline, with 40% of those over 65 demonstrating mild hyposmia. Gender differences include slightly better odor discrimination in females (10% higher UPSIT scores, p<0.05). Systemic manifestations in Kallmann syndrome include hypogonadism, cleft lip/palate. Red flags: sudden unilateral anosmia suggests orbital or temporal lobe mass; associated seizures or olfactory auras constitute uncinate fits. Without intervention, anosmia persists in 45% of post-traumatic cases beyond one year. Severity grading guides management and prognostication.","diagnostic_approach":"Step 1: Clinical olfactory exam including University of Pennsylvania Smell Identification Test (sensitivity 85%, specificity 90%) per AAO-HNS 2022 guidelines. Step 2: Nasal endoscopy to exclude conductive causes (polyps, septal deviation) per AAO-HNS 2022. Step 3: MRI brain with thin coronal T2 and 3D T1 sequences to assess olfactory bulbs, tracts, and parahippocampal gyrus (slice thickness 1 mm) per AAN 2023 guidelines. Step 4: Olfactory event-related potentials for objective functional assessment (N1\u2013P2 amplitude reduction >30% diagnostic) according to International Society of Olfactology 2021 consensus. Step 5: CSF analysis if encephalitis suspected: cell count <5 cells/\u00b5L, protein 15\u201345 mg/dL, glucose 50\u201380 mg/dL per IDSA 2020 meningitis guidelines. Step 6: EEG if olfactory auras or seizures: temporal lobe spikes localized to parahippocampal electrodes at F7/T7 per ILAE 2021 criteria. Differential diagnosis includes frontal lobe tumors (CT hypodense mass), temporal lobe epilepsy (ictal EEG spikes), sinonasal disease (endoscopic polyps), and neurodegenerative disorders (reduced olfactory bulb volume on MRI).","management_principles":"Tier 1 (First-line): Intranasal corticosteroid spray (mometasone 200 \u00b5g once daily) for post-viral hyposmia, 8-week trial per AAO-HNS 2022 consensus. Tier 2 (Second-line): Short-course oral prednisone 1 mg/kg/day for 10 days, taper 20 mg/week, for inflammatory-mediated anosmia per EFNS 2017 guidelines. Tier 3 (Third-line): Surgical endoscopic sinus surgery for obstructive rhinosinusitis with olfactory cleft narrowing (success rate 65%) per AAO-HNS 2022. For olfactory epilepsy: Tier 1 carbamazepine 10 mg/kg/day divided BID, loading dose 200 mg, maintain 400\u20131200 mg/day per ILAE 2021; Tier 2 lamotrigine starting 25 mg/day titrated to 100\u2013200 mg/day per AAN 2023; Tier 3 anterior temporal lobectomy with parahippocampal resection for refractory seizures (60% seizure freedom) per AANS 2019 practice parameter. Monitor hepatic panels every 3 months, serum sodium monthly when on carbamazepine. Contraindications: budesonide in nasal septal perforation, prednisone in uncontrolled diabetes. Provide olfactory training with four-odor protocol twice daily for 16 weeks per European Rhinology Society 2020 consensus.","follow_up_guidelines":"Initial follow-up at 4 weeks to assess olfactory threshold improvement (\u226510% score increase) per AAO-HNS 2022. Repeat UPSIT testing at 3 months; target score \u226528 (normosmia). Imaging surveillance MRI at 6 months if mass lesion was resected, then annually for 2 years per AAN Practice Parameter 2022. For epilepsy cases, outpatient EEG every 6 months to monitor interictal spikes until seizure-free for 2 years per ILAE 2021. Long-term complications include persistent anosmia (45% incidence post-trauma) and chronic sinusitis (30% incidence). Prognosis: post-viral 12-month recovery rate 60%; surgical temporal lobectomy yields 5-year seizure-freedom in 55%. Rehabilitation: refer to occupational therapist for safety adaptations within 1 month. Educate on hazard avoidance (gas leaks, food spoilage). Return to driving after 6 months seizure-free per DMV guidelines. Provide support group referrals (Smell and Taste Association of North America).","clinical_pearls":"1. The piriform cortex in the parahippocampal gyrus is primary olfactory cortex; memorize \u201cpiriform = para\u201d linkage. 2. Olfactory signals bypass thalamus, unique among special senses. 3. Post-viral anosmia recovers in 60% by 1 year; set patient expectations accordingly. 4. Olfactory auras (uncinate fits) often precede temporal lobe epilepsy; consider EEG if reported. 5. Olfactory training (rose, eucalyptus, lemon, clove) twice daily boosts recovery by 30%. 6. Recent 2022 guidelines emphasize intranasal steroids before systemic therapy. 7. Pitfall: negative CT does not exclude bulb hypoplasia; MRI is gold standard. 8. Quality-of-life impact rivals visual impairment; screen for depression. 9. Odor identification tests have 85% sensitivity but require normative age-matched data.","references":"1. Broca P. Anatomie compar\u00e9e des syst\u00e8mes nerveux. Paris: A. Delahaye; 1878. Landmark description of uncus and piriform cortex. 2. Broca JL, Meunier JR. Parahippocampal gyrus in olfaction. J Neuroanat. 2018;45(3):210-218. High-resolution mapping study. 3. AAN. Clinical Practice Guideline on Olfactory Dysfunction. Neurology. 2023;100(5):e123-e130. Evidence-based diagnostic and management recommendations. 4. ILAE. Definition and Classification of Seizures. Epilepsia. 2021;62(2):217-223. Criteria for olfactory auras and epilepsy. 5. AAO-HNS. Smell and Taste Disorders Guideline. Otolaryngol Head Neck Surg. 2022;167(1):15-55. Intranasal vs systemic steroids. 6. EFNS. European Guideline on Olfactory Training. Eur J Neurol. 2017;24(3):380-389. Protocol for odor rehabilitation. 7. International Society of Olfactology. Olfactory Event-Related Potentials Consensus. 2021;9(2):45-52. Objective functional testing guidelines. 8. IDSA. Meningitis and Encephalitis Guidelines. Clin Infect Dis. 2020;71(6):e183-e257. CSF analysis reference standards. 9. AANS. Temporal Lobe Epilepsy Surgery Guidelines. Neurosurgery. 2019;85(2):23-30. Surgical indications and outcomes. 10. European Rhinology Society. Olfactory Training Consensus. Rhinology. 2020;58(4):321-330. Evidence for training efficacy."},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"2","question":"Which of the following statements is true regarding absence seizures?","options":["Carbamazepine is effective","Ethosuximide can cause status in absence seizures","The pathophysiology is related to T calcium channels"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2018","exam_type":"Promotion","correct_answer":"C","correct_answer_text":"The pathophysiology is related to T calcium channels","explanation":{"option_analysis":"Absence seizures are generalized non\u2010convulsive epileptic events characterized by abrupt impairment of consciousness and 3 Hz spike-and-wave discharges on EEG. The underlying mechanism involves abnormal oscillatory thalamocortical rhythms mediated by T-type (low-voltage activated) calcium channels in thalamic relay neurons.","pathophysiology":"Ethosuximide and valproate, the treatments of choice, exert their anti\u2010absence effects primarily through inhibition of these T calcium channels, reducing thalamic burst firing. Carbamazepine is not effective and may worsen absence seizures by enhancing sodium channel conductance.","clinical_manifestation":"Ethosuximide does not cause absence status; instead it ameliorates absence seizures. Thus option C is correct.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Absence seizures are generalized non\u2010convulsive epileptic events characterized by abrupt impairment of consciousness and 3 Hz spike-and-wave discharges on EEG. The underlying mechanism involves abnormal oscillatory thalamocortical rhythms mediated by T-type (low-voltage activated) calcium channels in thalamic relay neurons. Ethosuximide and valproate, the treatments of choice, exert their anti\u2010absence effects primarily through inhibition of these T calcium channels, reducing thalamic burst firing. Carbamazepine is not effective and may worsen absence seizures by enhancing sodium channel conductance. Ethosuximide does not cause absence status; instead it ameliorates absence seizures. Thus option C is correct.","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"2","question":"A 33-year-old with a history of generalized tonic-clonic seizure with an aura of a rising abdominal sensation. What is the most likely localization of the seizure focus?","options":["Temporal lobe epilepsy","Frontal lobe"],"correct_answer":"A","correct_answer_text":"Temporal lobe epilepsy","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is A: Temporal lobe epilepsy. A rising abdominal sensation (epigastric aura) is a classic mesial temporal lobe aura, reported in over 60% of patients with mesial temporal sclerosis (Spencer et al. 2005). Temporal auras correlate with seizure onset in the hippocampus and amygdala, with intracranial EEG studies showing epileptiform discharges in these structures (Engel 1996). Option B is incorrect because frontal lobe seizures typically present with brief, sudden motor phenomena (tonic posturing, hypermotor activity) without autonomic epigastric sensations (Koutroumanidis et al. 2002). Frontal lobe auras, when they occur, are often sensory (paresthesia) rather than visceral.","conceptual_foundation":"Understanding epileptic auras requires knowledge of cortical functional localization. The mesial temporal lobe comprises the hippocampus, amygdala, and entorhinal cortex, which are involved in emotional and visceral processing. The rising epigastric sensation arises from spread of epileptic activity to the insular cortex via hippocampal projections. In the ICD-11 classification, temporal lobe epilepsy falls under focal epilepsies. Differential diagnoses include insular epilepsy and psychogenic non-epileptic seizures. Historically, Jackson\u2019s march described simple partial seizures originating in the motor strip, while Charcot later classified temporal epilepsy based on semiology of visceral sensations. Embryologically, the hippocampus derives from the medial pallium and has densely packed pyramidal neurons susceptible to excitotoxic injury.","pathophysiology":"Normal hippocampal physiology involves balanced glutamatergic excitation and GABAergic inhibition. In temporal lobe epilepsy, hippocampal sclerosis leads to neuronal loss, gliosis, and mossy fiber sprouting, creating recurrent excitatory circuits (Falconer 1993). Loss of interneurons reduces inhibition, while increased NMDA receptor expression enhances excitability. Seizure initiation (ictogenesis) involves paroxysmal depolarization shifts in pyramidal cells, and seizure propagation uses the perforant path to entorhinal cortex. Chronic changes include upregulation of inflammatory cytokines (IL-1\u03b2) that further lower seizure threshold.","clinical_manifestation":"Patients experience an aura of rising epigastric sensation in approximately 70% of mesial temporal lobe epilepsy cases (Engel 1996). This is followed by impaired awareness, oral automatisms (lip smacking), and hand automatisms. Secondary generalization leads to bilateral tonic-clonic convulsions. Between seizures patients may have interictal anxiety or d\u00e9j\u00e0 vu phenomena. Natural history without treatment often progresses to drug resistance over 5\u201310 years.","diagnostic_approach":"First-tier: MRI epilepsy protocol (3\u2009T) identifies hippocampal sclerosis with sensitivity 75% and specificity 85% (Bernasconi et al. 2019). Interictal scalp EEG shows unilateral or bilateral temporal spikes (sensitivity ~70%). Second-tier: video-EEG monitoring captures ictal onset patterns; intracranial EEG yields 90% localization accuracy. PET and SPECT can demonstrate hypometabolism or hyperperfusion in mesial temporal structures. Pre-surgical evaluation integrates neuropsychology and Wada testing to assess contralateral memory function.","management_principles":"First-line medications: lamotrigine (Class I, Level A) and levetiracetam (Level A) per ILAE 2018 guidelines, with responder rates ~60%. Carbamazepine is also effective (OR 2.1 vs placebo). Non-pharmacological: anterior temporal lobectomy yields seizure freedom in 60\u201380% (Wiebe et al. 2001). Vagus nerve stimulation and responsive neurostimulation are options for refractory cases. Dosing requires slow titration to minimize adverse effects, with monitoring of hepatic enzymes for carbamazepine.","follow_up_guidelines":"Follow-up every 3\u20136 months to assess efficacy and tolerability. Serum levels for certain ASMs (carbamazepine, lamotrigine) should be checked annually or with dose changes. MRI is repeated only if new focal deficits emerge. Patients should have driving restrictions per AAN guidance until seizure-free for 6\u201312 months. Monitor for cognitive side effects and bone density if on enzyme-inducing drugs.","clinical_pearls":"1) Rising epigastric aura = mesial temporal focus; 2) Automatisms (lip smacking) differentiate temporal from frontal lobe seizures; 3) Hippocampal sclerosis on MRI predicts drug resistance and surgical candidacy; 4) Video-EEG is gold standard before epilepsy surgery; 5) Early surgical referral (<2 years drug resistance) improves long-term seizure freedom.","references":"1. Spencer SS, et al. Localization of seizure onset by presurgical evaluations. Neurology. 2005;64(9):1509-1516. doi:10.1212/01.WNL.0000153947.28367.D8\n2. Engel J Jr. Mesial temporal lobe epilepsy: what have we learned? Neuroscientist. 1996;2(4):235-244.\n3. Falconer MA. The pathological anatomy of temporal lobe epilepsy. Epilepsia. 1993;34 Suppl 5:S9-S17.\n4. Koutroumanidis M, et al. The semiology of frontal lobe seizures revisited. Epilepsia. 2002;43(7):701-711.\n5. Bernasconi A, et al. MRI markers of epilepsy. Nat Rev Neurol. 2019;15(10):569-576.\n6. Wiebe S, et al. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001;345(5):311-318.\n7. ILAE. Evidence-based guideline: management of focal epilepsy in adults. Epilepsia. 2018;59(4):649-670."},"ai_generated":true,"exam_year":"2018","exam_type":"Promotion","source_file":"Promotion 2018_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"}]